Xylopic Acid-Amodiaquine and Xylopic Acid-Artesunate Combinations are Effective in Managing Malaria in \textit{Plasmodium Berghei}-infected Mice.

Silas Acheampong Osei$^{1,2}$, Robert Peter Biney$^{2,3}$, Ernest Obese$^{2,3}$, Mary Atta-Panyi Agbenyeku$^1$, Isaac Yaw Attah$^{1,2}$, Elvis Ofori Ameyaw$^{1,2}$*, Johnson Nyarko Boampong$^{1,2}$.

$^1$Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
$^2$School of Pharmacy and Pharmaceutical Sciences, University of Cape Coast, Cape Coast, Ghana.
$^3$Department of Pharmacology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.

*Corresponding author

ABSTRACT

\textbf{Background:} Evidence of plasmodium resistance to some of the current antimalarial agents makes it imperative to search for newer and effective drugs to combat malaria. Therefore, this study evaluated whether the co-administrations of xylopic acid-amodiaquine and xylopic acid-artesunate combinations will produce synergistic antimalarial effect.

\textbf{Methods:} Antiplasmodial effect of xylopic acid (XA: 3, 10, 30, 100, 150 mg kg$^{-1}$), artesunate (ART: 1, 2, 4, 8, 16 mg kg$^{-1}$), and amodiaquine (AQ: 1.25, 2.5, 5, 10, 20 mg kg$^{-1}$) were evaluated in \textit{Plasmodium berghei} ANKA-infected mice to determine respective ED$_{50}$s. Artemether/lumefantrine (AL: 1.14/6.9) \textit{p.o.} was used as the positive control. XA/ART and XA/AQ were subsequently administered in a fixed-dose combination of their ED$_{50}$s (1:1) and the combination fractions of their ED$_{50}$s (1/2, 1/4, 1/8, 1/16, and 1/32) to determine the experimental ED$_{50}$s (Z$_{exp}$). An isobologram was constructed to determine the nature of the interaction between XA/ART, and XA/AQ combinations by comparing Z$_{exp}$ with the theoretical ED$_{50}$ (Z$_{add}$). Body weight and 30-day survival post-treatment were additionally recorded.

\textbf{Results:} ED$_{50}$s for XA, ART, and AQ were 9.0 ± 3.2, 1.61 ± 0.6, and 3.1 ± 0.8 mg kg$^{-1}$ respectively. The Z$_{add}$, Z$_{exp}$ and interaction index for XA/ART co-administration was 5.3 ± 2.61, 1.98 ± 0.25 and 0.37, respectively while that of XA/AQ were 6.05 ± 2.0, 1.69 ± 0.42, and 0.28 respectively. The Z$_{exp}$ for both combination therapies lay significantly (p<0.001) below the additive isoboles showing XA acts synergistically with both ART and AQ in clearing the parasites. High doses of XA/ART combination significantly (p<0.05) increased the survival days of infected mice with a mean hazard ratio of 0.40 while all the XA/AQ combination doses...
showed a significant (p<0.05) increase in the survival days of infected mice with a mean hazard ratio of 0.27 similar to AL. Both XA/ART and XA/AQ combined treatments significantly (p<0.05) reduced weight loss.

**Conclusion:** Xylopic acid co-administration with either artesunate or amodiaquine produces a synergistic anti-plasmodial effect in mice infected with *Plasmodium berghei* ANKA.

**Key words:** Antimalarial drugs, Combination therapies, Isobolographic analysis, Xylopic acid, Artesunate, Amodiaquine, synergism, *Plasmodium berghei*.

**INTRODUCTION**

Regardless of the efforts put in place in the 21st century to eradicate the staggering toll of malaria on human health, the global burden of the disease remains, especially, in several tropical countries. World health organization (WHO) estimated that 40% of the world’s population is susceptible to malaria infections (1). A recent report indicates that 228 million cases of malaria occurred in 2018, which resulted in 405,000 deaths, mostly in sub-Saharan Africa (2). About 93% (213 million) of the cases in 2018 were recorded in the WHO African Region. Ghana and Nigeria are the two countries among the 10 highest-burden countries in Africa which recorded an increase in malaria cases from 2017 to 2018. Children under five years succumb to the devastating effects of the disease accounting for 272,000 (67%) of all malaria deaths worldwide (2). The incidence rate and the death toll of malaria on children make the disease a major global infectious disease.

*Cinchona* alkaloids (quinine and quinidine) and artemisinin derivatives (artesunate, artemether, and artemotil) are the two classes of medicines available for the treatment of severe and uncomplicated malaria, respectively. *Plasmodium falciparum* has developed resistance to antimalarial agents such as chloroquine in the past and there are reports of growing resistance of *P. falciparum* to artemisinin derivatives in South-east Asia (3). Anectodal study in six West-African countries including Ghana showed increased failure rates (10%) in malaria treatment
with artemisinin-based combination therapies (4). Some malaria vaccines (Plasmodium falciparum sporozoite vaccine (PfSPZ), Chemoprophylaxis vaccination (CVac), Genetically attenuated parasite vaccine (GAP), RTS,S/AS01) are at various stages of development but not a clinically approved malaria vaccine therefore (5) making the search for newer, more effective antimalarial agent still relevant.

Drug combination therapies (DCTs) are pertinent to the optimum control of malaria in developing countries (6) because they provide improved efficacy and might also give synergistic activity. Due to the rapid spread of drug resistance among parasites worldwide, the initial use of single drugs as monotherapies has given way in the last decades to combination therapies of two or more drugs especially the use of agents with different modes of action to improve efficacy and reduce resistance (Whitty and Staedke, 2005; Martinelli et. al., 2008). Drug combinations also enhance the probability that one agent can be at least clinically active in the case of parasite resistance to the drug. Example, in East Africa, malaria parasites are resistant to both amodiaquine and sulfadoxine-pyrimethamine (SP), but the combination of these two agents still gives an excellent antimalarial efficacy (7-9).

Natural products are essential in the drug discovery process, and there is no exception in antimalarial agents. Medicinal plant extracts have been a source for antimalaria drug discovery for long, and their treatment for malaria have been successful (10). About 160 plant families have been established to have antimalarial properties. From these families, more than 1200 species have been documented to have antimalarial properties (1) including Xylopia aethiopica which is used to treat malaria by Ghanaian herbal practitioners (11).

Xylopic acid, a kaurene diterpene, is the major constituent of the fruits of Xylopia aethiopica and has been reported to possess antimalarial properties in Plasmodium berghei-infected ICR mice. Furthermore, it significantly reduced the lipopolysaccharide- (LPS) induced fever in Sprague-
Dawley rats (11). Thus, xylopic acid possesses prophylactic and curative antimalarial effects along with antipyretic and analgesic properties, making it a promising antimalarial agent. Artesunate, amodiaquine, and xylopic acid have all been shown to be effective in combination therapies as demonstrated by Ameyaw and colleagues on the synergistic effect of xylopic acid in combination with cryptolepine in clearing malaria parasites in a malaria experimental model (12). Similarly, the antimalarial activity of amodiaquine and artesunate was enhanced when combined with lopinavir/ritonavir (13). In the present study, we tested the efficacy of xylopic acid/amodiaquine and xylopic acid/artesunate combination therapy in mice infected with *Plasmodium berghei* ANKA.

**METHODS**

**Xylopic acid extraction**

Xylopic acid was extracted from *Xylopia aethiopica* as previously described (14-16). Fresh unripe fruits of *Xylopia aethiopica* purchased from the Ho Central Market in Ghana were shade-dried and pulverized with a hammer mill. For every 100 g of plant material, 300 ml of petroleum ether was used as a solvent for maceration. The mixture of *Xylopia aethiopica* and petroleum ether was left to stand for three days with continuous shaking every 24 hours. Whatman filter paper was used to filter the mixture and left to stand overnight under dark conditions. The filtrate was then concentrated with a Rotary evaporator (Heidolph Labo Rota, 4002) at 120 revolutions per minute and 40-55°C. The concentrate was left to stand for 72 h and 3 drops of ethyl acetate added to facilitate the crystallization of crude xylopic acid crystals. Crude xylopic acid was washed several times with petroleum ether, and dissolved in absolute ethanol for purification by recrystallization. The purity of the xylopic acid was assessed by thin-layer chromatography using petroleum ether and ethyl acetate (9:1) as the solvent system. Pure xylopic acid was used as a reference and both compounds gave Rf of 0.53.
Experimental animals
Six to ten weeks-old female ICR mice purchased from Centre for Medicinal Plant Research, Akuapim-Mampong, Ghana, were used for the study. They were housed in stainless steel cages (16.5 × 11.0 × 13.5 cm$^3$) with beddings made from softwood shavings. The animals were kept under appropriate laboratory conditions and fed with normal commercial pellet diet purchased from Agricare, (Kumasi, Ghana) and water *ad libitum*. The cages were kept in the Department of Biomedical Sciences animal holding facility, University of Cape Coast, and the wood shavings were replaced every 3 days and disinfected with 70% alcohol. The facility had a 12/12 h light/dark cycles and a mean temperature of 21°C.

Drugs, Chemicals, and Reagents
Artemether/lumefantrine combined tablets (20/120 mg), artesunate, and amodiaquine were acquired from Novartis Pharma AG Basel, Switzerland. Hydrochloric acid, Giemsa stain, absolute methanol, chloroform, petroleum ether, ammonium hydroxide, 96% ethanol, liquid paraffin, Tween 20 and ammonium chloride were also purchased from Sigma Aldrich. St Louis, MO, USA.

*Plasmodium berghei* ANKA parasite acquisition and inoculation
Chloroquine-sensitive strain rodent malaria parasite, *Plasmodium berghei* ANKA (PbA), was acquired from Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana and by a continuous passage in mice intraperitoneally every six days (17). Once high parasitemia (30-40%) was established in a donor mouse, it was sedated under chloroform, following Hoff’s technique (18). Blood was collected by cardiac puncture and transferred into EDTA tubes, capped, and topped with Phosphate Buffered Saline (PBS). The mixture containing blood, EDTA, and PBS were washed three times by centrifuging with hematocrit centrifuge, at 15000 rpm for 6-7 minutes to obtain pellets. Total inoculum concentration of $1.74 \times 10^7$ *P. berghei*
ANKA parasitized erythrocytes were prepared and each mouse was inoculated with 0.20 ml of PBS containing 1.2×10⁶ parasitized red blood cells

**Bodyweight measurement**
Mice body weights were measured on days 0 and day 7 post-infection following a procedure described by Dikasso and colleagues (19) using a top pan balance (Toledo® Metler, Japan).

**Antimalarial activity**

*In vivo anti-plasmodial assay of xylopic acid, artesunate and amodiaquine monotherapies*
To confirm the reported anti-malaria properties of xylopic acid (XA), artesunate (ART), and amodiaquine (AQ), and also determine their ED₅₀ values for the isobolographic analysis, the anti-plasmodial activity of each compound was assessed. After infection, mice were assigned to 18 groups (n=5). Mice in all groups were inoculated with *P. berghei* except Group 18 mice which served as naïve control. Seventy-two hours post-inoculation (day 3), all groups of animals were treated once daily by oral administration with a gastric gavage with either xylopic acid (3, 10, 30, 100, 150 mg kg⁻¹), artesunate (1, 2, 4, 8, 16 mg kg⁻¹), amodiaquine (1.25, 2.5, 5, 10, 20 mg kg⁻¹), artemether/lumefantrine (1.14/6.9 mg kg⁻¹), or vehicle, 10 ml kg⁻¹ (naïve and sham control). The ED₅₀ values obtained as fitted midpoints of XA, ART, and AQ were determined by iterative curve fitting of log-dose responses of XA, ART, and AQ. Mice were observed at 12 h intervals for death and the median survival and hazard ratio over a 30-day period computed.

*In vivo isobolographic assessment of xylopic acid-artesunate co-administration on PbA-induced malaria.*
To assess the antiplasmodial property of xylopic acid-artesunate (XA/ART) co-administration on established *Plasmodium berghei* infection, six to ten weeks female ICR mice were each inoculated with 1.2 ×10⁶ in 0.20 ml PBS and assigned to 8 groups (n=5). On day 3, each group received either fixed ratio (1:1) of the ED₅₀ values of XA and ART (9+1.6 mg kg⁻¹) or combinations of fractions of the respective ED₅₀ values: ED₅₀ (XA/ART)/2, (4.5+0.8 mg kg⁻¹), ED₅₀ (XA/ART)/4 (2.25+0.4 mg kg⁻¹), ED₅₀ (XA/ART)/8, (1.13+ 0.2 mg kg⁻¹), ED₅₀ (XA/ART)/16 (0.6 + 0.1 mg
kg\(^{-1}\). Positive control (AL) and negative control (sham) mice received 1.14/6.9 mg kg\(^{-1}\) AL and 10 ml kg\(^{-1}\) vehicle, respectively.

**In vivo isobolographic assessment of xylopic acid-amodiaquine co-administration on PbA-induced malaria.**

To assess the anti-plasmodial property of xylopic acid-amodiaquine (XA/AQ co-administration, on established *Plasmodium berghei* infection, six to ten weeks female ICR mice were each inoculated with 1.2 \(\times 10^6\) in 0.2 ml PBS and assigned to 8 groups (n=5). Seventy-two hours later, each group received fixed ratio (1:1) or combinations of fractions of the respective ED\(_{50}\) values of (9 +3.1 mg kg\(^{-1}\)), (4.5+ 1.6 mg kg\(^{-1}\)), (2.25+0.8 mg kg\(^{-1}\)), (1.125+ 0.4 mg kg\(^{-1}\)), (0.6+ 0.2 mg kg\(^{-1}\)), ED\(_{50}\) (XA/AQ), ED\(_{50}\) (XA/AQ)/2, ED\(_{50}\) (XA/AQ)/4, ED\(_{50}\) (XA/AQ)/8, and ED\(_{50}\) (XA/AQ)/16, respectively. Positive control (AL) and negative control (sham) mice received 1.14/6.9 mg kg\(^{-1}\) AL and 10 ml kg\(^{-1}\) vehicle, respectively

**Percentage Chemo-suppression and parasitemia evaluation**

Parasitemia was tracked using thin blood smears made daily for 5 days by collecting three drops of blood from the tail of each mouse, fixed in absolute methanol, and stained in 10% Giemsa for 10 minutes to determine parasitemia. The slides were microscopically examined at \(\times 100\) magnification. Parasitemia was checked by counting infected red blood cells in hundred fields, divided by the total red blood cells in the hundred fields and then multiplied by hundred and percentage parasitemia calculated as follows:

\[
\% \text{Parasitemia} = \frac{\text{Number of Plasmodium berghei–infected erythrocytes}}{\text{Total number of erythrocytes}} \times 100
\]

Chemosupression or percentage inhibition of parasitemia was computed by employing the following formula
\[ \% \text{ inhibition} = \frac{\text{Mean parasitaemia of negative control} - \text{Mean parasitaemia of test drug}}{\text{Mean parasitaemia of negative control}} \times 100 \]

**Data analysis**

All statistical analyses were computed with the windows version of GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). Data were considered significant at \( p < 0.05 \) and were presented as the mean ± SEM. Tukey’s honest significant difference (HSD) test was used as *post hoc* test. Two isobolograms which consisted of the ED\(_{50}\) of XA on the ordinate and ED\(_{50}\) of ART or AQ on the abscissa connected with a line of additivity were constructed. The ED\(_{50}\) of each drug was determined by linear regression analysis of the log dose-response curve (and a T-test was used for the comparison to a theoretical additive ED\(_{50}\) i.e. \( Z_{add} \)). \( Z_{add} \) was computed with the following formulae:

\[
Z_{add} = (f) \text{ ED}50 \text{ of ART} + (1-f) \text{ ED}50 \text{ of XA}
\]

and

\[
Z_{add} = (f) \text{ ED}50 \text{ of AQ} + (1-f) \text{ ED}50 \text{ of XA}
\]

where \( f \) = fraction of each component in the mixture/ combination while the Var (variance) of \( Z_{add} \) was computed as follows:

\[
\text{Variance of } Z_{add} = f^2 (\text{Var ED}50 \text{ of CYP}) + (1-f)^2 (\text{Var ED}50 \text{ of XA})
\]

SEMs were calculated from these variances and fixed according to the drug’s ratio in the combination. If the effect of a drug combination was statistically different (ED\(_{50}\) significantly lower) and higher than the theoretically calculated equieffect of a drug combination in the same proportion, it has a supra-additive or synergistic effect.
RESULTS

*In vivo* anti-malarial assay of xylopic acid, artesunate, and amodiaquine monotherapies

**Effects of XA, ART and AQ monotherapy on body weight**

Amodiaquine and artesunate treatment groups significantly reduced weight loss in mice infected with *P. berghei* (*p*=0.001). In XA-treated groups, loss in body weight was not statistically significant. High doses of artesunate (8 mg/kg) and amodiaquine (10 mg/kg) showed an increase in body weight similar to the naïve and AL groups (Fig 1).

![Graphs showing body weight changes](image)

**Fig 1.** Bodyweight before infection and after treatment (left panel) and percentage change in body weight (right panel) for (a, b) xylopic acid, (c, d) artesunate, and (e, f) amodiaquine treated groups. Data are presented as mean ± SEM (n=5), *p* < 0.05.
**Effects of XA, ART and AQ monotherapy on post-treatment survival**

Artemether/lumefantrine-treated animals had 26 median survival days with a hazard ratio of 0.20 in the 30 days survival test (fig 2), representing the highest survival days and lowest hazard ratio in the treatment groups. Middle doses of XA (30 mg/kg), AQ (10 mg/kg) and high doses of ART treated groups also significantly increased survival days in the 30 days survival test (p< 0.05) (Table 1, fig 2).

**Table 1. 30-day survival analysis of *Plasmodium berghei* ANKA-infected mice after treatment with either xylopic acid, artesunate, amodiaquine or artemether/lumefantrine**

| Treatment (mg/kg) | Median Survival (days) | Hazard Ratio (Log-rank) | p-value |
|------------------|------------------------|-------------------------|---------|
| Naïve            | 30                     | -                       | -       |
| Sham             | 11                     | -                       | -       |
| XA               |                        |                         |         |
| 3                | 14                     | 0.49                    | 0.2017  |
| 10               | 15                     | 0.49                    | 0.2017  |
| 30               | 21                     | 0.15                    | 0.0269* |
| 100              | 17                     | 0.46                    | 0.1401  |
| 150              | 17                     | 0.32                    | 0.0272* |
| ART              |                        |                         |         |
| 1                | 12                     | 0.84                    | 0.7501  |
| 2                | 15                     | 0.51                    | 0.2088  |
| 4                | 17                     | 0.39                    | 0.0689  |
| 8                | 18                     | 0.25                    | 0.0064**|
| 16               | 24                     | 0.20                    | 0.0064**|
| AQ               |                        |                         |         |
| 1.25             | 15                     | 0.47                    | 0.1843  |
| 2.5              | 15                     | 0.48                    | 0.1842  |
| 5                | 16                     | 0.53                    | 0.2097  |
| 10               | 23                     | 0.25                    | 0.0064**|
| 20               | 16                     | 0.40                    | 0.0812  |
| AL               | 26                     | 0.20                    | 0.0018**|
Fig 2. Kaplan Meier survival curves comparing the survival of *P. berghei*-infected mice between sham and various treatment groups for 30 days post-infection. * = p<0.05, **=p<0.01

**Anti-plasmodial effects of XA, ART and AQ monotherapy**

The antimalarial activities of XA, ART, and AQ were individually evaluated in a mouse model of *P. berghei*. Infection was established on day 3 (72 hours post-infection) for all groups. ED$_{50}$s for xylopic acid, artesunate, and amodiaquine were 9.0±3.2, 1.61±0.6, and 3.1±0.8 mg/kg. By these results, the artesunate was 1.9 times more potent than amodiaquine, and amodiaquine was 2.9 times more potent than xylopic acid (fig 3).
Fig 3. Log dose-response curves of percentage chemosuppression in *P. berghei*-infected mice administered daily with xylopic acid, artesunate, or amodiaquine over 5 days. Data are presented as mean ± SEM (n=5)
In vivo assessment of xylopic acid-artesunate and xylopic acid-amodiaquine co-administration of PbA-induced malaria

Effects of XA+ART and XA+AQ combination on weight loss

AL, 5.3 mg/kg XA+ART, 10.6 mg/kg XA+ART, 6.1 mg/kg XA+AQ, and 12.1 XA+AQ treated groups significantly reduced loss in body weight compared to the sham-treated group (p< 0.05) (fig 4).

Fig 4. Bodyweight before infection and after treatment and percentage change in body weight for (a, b) xylopic acid-artesunate, and (c, d) xylopic acid- amodiaquine combination-treated groups. Data are represented as mean ± SEM (n=5), p<0.05.
Effects of XA+ART and XA+AQ combination on parasetemia and chemosuppression.

Percentage chemosuppression for the highest combination doses of both XA/ART (table 2) and XA/AQ (table 3) suppressed parasite growth similar to artemether/lumefantrine (Fig 5). The ED₅₀s for xylopic acid-artesunate and xylopic acid-amodiaquine were 1.98 ±0.33 and 1.69 ± 0.83 respectively (fig 6).

Fig 5. Percentage chemosuppression for (a) xylopic acid-artesunate and (b) xylopic acid-amodiaquine treated P. berghei-infected mice. Data are presented as mean ± SEM, (n=5), p<0.05.

Fig 6. Log dose-response curves for P. berghei-infected mice treated daily with xylopic acid/artesunate (XA+ART) combination, and xylopic acid-amodiaquine (XA+AQ) combination over 5 days. Data are presented as mean ± SEM (n=5).
Table 2. Percentage parasitemia and chemosuppression of mice treated with different doses of xylopic acid + artesunate combination for five days.

| Treatment (ED_{50} mg/kg) | Dose (mg/kg) | % Chem supp Day 6 |
|---------------------------|--------------|-------------------|
| Sham                      | 0.50 ml      | -                 |
| (XA/ART)/16               | 0.6:0.1      | 21.5 ± 0.6        |
| (XA/ART)/8                | 1.13:0.2     | 24.1 ± 0.5        |
| (XA/ART)/4                | 2.25:0.4     | 52.2 ± 0.8        |
| (XA/ART)/2                | 4.5:0.8      | 66.8 ± 0.1        |
| (XA/ART) 10,6             | 9.0:1.61     | 75.7 ± 1.2        |
| AL 1.14                   | -            | 84.6 ± 1.6        |

Data are presented as mean ± SEM.

Table 3. Percentage parasitemia and chemosuppression of mice treated with different doses of xylopic acid + amodiaquine combination for five days.

| Treatment (ED_{50} mg/kg) | Dose (mg/kg) | % Chem supp Day 6 |
|---------------------------|--------------|-------------------|
| Sham                      | 0.50 ml      | -                 |
| (XA/AQ)/16                | 0.6:0.2      | 41.2 ± 1.3        |
| (XA/AQ)/8                 | 1.125:0.4    | 43.9 ± 1.9        |
| (XA/AQ)/4                 | 2.25:0.8     | 56.4 ± 0.8        |
| (XA/AQ)/2                 | 4.5:1.6      | 68.4 ± 1.3        |
| (XA/AQ) 12.1              | 9.0:3.1      | 79.8 ± 0.9        |
| AL 1.14                   | -            | 88.3 ± 0.4        |

Data are presented as mean ± SEM.

**Survival analysis for combination therapy**

The XA/AQ combination doses significantly delayed death in PbA infected mice in a 30-days survival test, similar to the AL treated group. Likewise, the high doses of XA/ART combination increased the survival days of the PbA infected mice (table 4, fig 7).
Table 4. Thirty-day survival analysis of *Plasmodium berghei* ANKA-infected mice after treatment with xylopic acid and amodiaquine, and xylopic acid and artesunate

| Treatment (mg/kg) | Median Survival (days) | Hazard Ratio (Log-rank) | p-value |
|------------------|------------------------|-------------------------|---------|
| Sham             | 10.5                   |                         |         |
| (XA/ART)         |                        |                         |         |
| 0.7              | 10                     | 0.52                    | 0.1766  |
| 1.3              | 12                     | 0.59                    | 0.2941  |
| 2.7              | 16                     | 0.35                    | 0.0374* |
| 5.3              | 16                     | 0.35                    | 0.0374* |
| 10.6             | 19                     | 0.23                    | 0.0021**|
| (XA/AQ)          |                        |                         |         |
| 0.8              | 13                     | 0.34                    | 0.0297* |
| 1.6              | 15                     | 0.14                    | 0.0297* |
| 3.1              | 15                     | 0.33                    | 0.0224* |
| 6.1              | 20                     | 0.29                    | 0.0112* |
| 12.1             | 24                     | 0.23                    | 0.0021**|
| AL               | 27                     | 0.21                    | 0.0021**|
Figure 7. Kaplan Meier survival curves comparing the 30 days-post treatment survival of *P. berghei*-infected mice treated with XA/ART, XA/AQ, or AL.

**Isobolographic analysis of antiplasmodial effects of XA and ART, and XA and AQ co-administration.**

Xylopic acid-artesunate co-administration had a theoretical ED$_{50}$ ($Z_{add}$) of 5.3±2.61, whereas the experimental ED$_{50}$ ($Z_{exp}$) was obtained as 1.98±0.25 (Table 5). Also, the co-administration of xylopic acid and amodiaquine had a theoretical ED$_{50}$ value of 6.05±2.0; however, the experimental ED$_{50}$ was 1.69 ± 0.42. Thus, the $Z_{exp}$ for both combinations lies significantly below the line of additivity since the interaction index was calculated to be 0.37 and 0.28 for xylopic acid-artesunate and xylopic acid-amodiaquine co-administration, respectively (Fig 8).
Figure 8. Isobologram of the co-administration of xylopic acid and artesunate, and xylopic acid and amodiaquine. Filled circles show theoretical ED$_{50}$±SEM, while open circles show experimental ED$_{50}$ ± SEM. The line of additivity connects the ED$_{50}$ of xylopic acid on the abscissa to that of artesunate and amodiaquine on the ordinate.

Table 5. Theoretical (Z$_{\text{add}}$), and experimental (Z$_{\text{exp}}$) ED$_{50}$ of xylopic acid and artesunate, and xylopic acid and amodiaquine co-administration in the anti-malarial assay

| ED$_{50}$s (XA/ART 1:1) | Anti-malarial activity | ED$_{50}$s (XA/AQ 1:1) | Anti-malarial activity |
|------------------------|-----------------------|------------------------|-----------------------|
| Z$_{\text{add}}$ (mg/kg) | 5.3±2.61              | Z$_{\text{add}}$ (mg kg$^{-1}$) | 6.05±2.0              |
| Z$_{\text{exp}}$ (mg/kg) | 1.98±0.25             | Z$_{\text{exp}}$ (mg kg$^{-1}$) | 1.69±0.42             |
| Interaction index     | 0.37                  | Interaction index     | 0.28                  |

Data are presented as mean ± SEM

DISCUSSION

*Plasmodium falciparum* has developed resistance to antiplasmodial agents over the years and has been reported to acquire resistance to currently used antimalarial drugs (20). Growing evidence of the resistance of *P. falciparum* to even artemisinin derivatives calls for the urgent need for more efficient and safer antimalarials and nature remains a key source for such novel antimalaria agents (21). Combination therapy is a good strategy in antimicrobial chemotherapy because it enhances the probability of sustained efficacy in the advent of parasite resistance to one agent (22). The combination also helps in preventing the development of resistance due to their multiple mechanisms of action making evasion by the parasite significantly difficult. Combination therapy also improves efficacy when the agents act synergistically (7). Against this background, this study examined the effectiveness of combining each of two established antimalarial agents, artesunate and amodiaquine, with an investigational antiplasmodial agent, xylopic acid.
Xylopic acid, extracted from the unripe fruits of *Xylopia aethiopica* has been examined previously to have antiplasmodial, anti-inflammatory, antipyretic (11), and analgesic (15) properties. Also, it has been recently reported to act synergistically when combined with other plant-derived antiplasmodial compounds such as cryptolepine (12). These properties are crucial in the management of malaria symptomatology, making xylopic acid a potential antimalaria agent for further drug development and a good candidate for combination therapy in antimalaria chemotherapy.

Combining xylopic acid with either artesunate or amodiaquine showed a remarkable suppression in parasite growth similar to the artemether/lumefantrine. Although, monotherapy of XA, ART, and AQ also suppressed parasite growth compared to artemether/lumefantrine it occurred at higher doses. An isobolographic analysis was employed to determine the enhanced or improved potency and efficacy of xylopic acid-artesunate, and xylopic acid-amodiaquine combination therapies. An isobolographic analysis gives a central basis for evaluating whether a biological response induced by a mixture of agents is smaller, equal, or greater on the concept of dose additivity and the basis of the components or agents’ individual activities (23). The co-administration of xylopic acid and artesunate showed significant antiplasmodial activity in comparison to the sham-treated mice. The isobologram showed that when xylopic acid and artesunate are administered together, the $Z_{exp}$ was significantly below the line of additivity (“additive” isobole) and the $Z_{add}$, which means the two drugs have a synergistic anti-plasmodial effect. The interaction index of 0.37, which is significantly less than 1, confirms a synergistic relationship (24) and a supra-additive effect between artesunate and xylopic acid.

Compared to a recent study by Ameyaw et al. (12), combining xylopic acid and artesunate gave a higher supra-additivity and synergistic interaction than xylopic acid and cryptolepine combination, probably, due to the high synergistic property of artesunate (25-27). Nevertheless,
xylopic acid-cryptolepine co-administration showed a higher parasite clearance rate of 78% for the higher dose combination compared to the 75% for the higher dose combination of xylopic acid and artesunate. Another study which examined the chemotherapeutic interactions between antimalarial drugs and antiretroviral drugs observed the increase in antimalaria activity when ART was combined with lopinavir/ritonavir (LR) on day 5 post-infection in mice infected with \textit{P. berghei} (13) confirming the synergistic interaction of artesunate with other potent drugs.

The observed increased antiplasmodial activity of XA/ART combination could also be attributed to the two drugs interacting with several targets in the parasite. XA inhibits plasmodium dehydrogenase (28), an enzyme which catalyzes the reduction of pyruvate to lactate, crucial for energy production, whilst artemisinin derivatives are believed to undergo reductive activation of the peroxide group in the presence of ferrous ion which is released upon hemoglobin digestion within the food vacuole of the parasite (12, 29). This forms a carbon-centered radical which alkylates vital parasite proteins such as heme and membrane-associated parasite proteins (30, 31). Thus, the inhibition of different metabolic steps in plasmodium hemoglobin digestion of parasite glycolysis might contribute to the enhanced antiplasmodial activity of ART and XA.

Furthermore, the anti-inflammatory properties of xylopic acid may have contributed to the limiting survival of the parasite. Osafo and colleagues recently reported the anti-inflammatory properties of xylopic acid against various phlogistic agents (Bradykinin, serotonin, carrageenan, histamine, and prostaglandin E\textsubscript{2}). XA inhibited albumin denaturation, and also maximal edema and average paw thickness induced by the phlogistic agents for both prophylactic and therapeutic studies. It also inhibited the arachidonic acid pathway (32, 33). Inflammation plays a key role in the pathogenesis of malaria. Following \textit{PBA} infection, splenic dendritic cells, CD8\textalpha\textsuperscript{+} and Clec9A\textsuperscript{+} phagocytose, and cross-present parasite antigens which lead to the priming of parasite-specific CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells. Circulating parasitized red blood cells (pRBC) adhere to the
endothelium of blood vessels releasing inflammatory ligands such as hemozoin crystals which contain parasite DNA. These stimuli are responded by the release of cytokines and chemokines leading to the upregulation of adhesion molecules (ICAM, VCAM) and receptors (CXCR3) capable of presenting antigens (34). When adhesion molecules are upregulated, they aid in the primary rolling and tethering interactions between lymphocytes, granulocytes, and monocytes to endothelial cells at sites of tissue injury. If perturbed endothelial cells interact with monocytes along with synergistic action of proinflammatory molecules, they potentially exacerbate tissue factor expression and subsequently activate endothelial cells sustaining coagulation-inflammation cycle (35-38), hence, promoting the “vicious” cycle of coagulation-inflammation of sepsis, which is found to be crucial in malaria pathogenesis. Also, the adherence of parasites to the endothelium with the help of upregulated adhesion molecules following inflammation helps in the survival of parasites. Hence, the acute anti-inflammatory properties might prevent the coagulation-inflammation cycle contributing to the limited growth and survival of mice treated with xylopic acid-amodiaquine, and xylopic acid-artesunate combination.

*Plasmodium* parasites have over the years evolved several biomolecular strategies for escaping immune response to secure parasite survival in the host. One-way parasites achieve immune escape is via the exploitation of host components such as inflammation and platelets that can cause infected red blood cells (iRBCs) and uninfected RBCs to agglutinate promoting the appropriate microenvironment for sequestration (39-41). The release of a collection of mediators of inflammation may either result in an exacerbated immune response leading to pathology (42). CD4+ T-helper cells have been reported to be involved in malaria conferring protection. However, they have also been implicated in immune evasion and malaria pathogenesis (43). Despite all this, the demonstrated significant anti-inflammatory properties of XA (32, 44) might have prevented the poor outcome of malaria in the XA-ART, XA-AQ treated groups.
A combination of xylopic acid and amodiaquine showed enhanced activity due to their synergistic interaction. Like the XA/ART combination, XA/AQ interaction also showed an interaction index of 0.13, which is significantly different from 1. XA/AQ isobologram lay below the line of additivity, confirming the synergistic interaction between the two compounds. The precise molecular mechanisms by which these two agents act is not very clear, but several proteins in the parasite might be a target. AQ metabolite (desethylamodiaquine) is thought to accumulate in parasites food vacuole preventing the conversion of toxic heme produced due to intraerythrocytic parasite digestion of hemoglobin into crystalline hemozoin which is non-toxic to the host but irreversibly toxic to the parasite as a result of the build-up of heme levels (31). Previous works on antimalarial combination therapies have shown that, when aspartyl PI is combined with other hemoglobin digestion inhibitors, it acts synergistically (31) but acts antagonistically with vacuole plasmepsin inhibitors (45). The mechanisms employed by individual drugs of the combination to inhibit metabolic steps in the digestion of hemoglobin may result in the enhanced antimalarial activity of XA in the presence of AQ and ART shown in this study.

In malaria treatment, like any other infectious diseases, it is crucial not only to pay attention to the pathogen but also the reduction of the symptoms of the infection which independently increase the pathogen burden (46). Among the several general features of malaria infection is the loss of body weight. Weight loss can be attributed to metabolic function disturbance and hypoglycemia caused by malaria parasite infection (47-49). Hypoglycemia in malaria patients can also be attributed to the increase in glucose uptake by the febrile host and the parasite. Alternatively, the host’s glucose production may be impaired (50). Thus, an ideal antimalarial drug is anticipated to prevent the decrease in body weight of mice due to rising parasitemia, which is crucial for mice survival. AQ and ART prevented the loss of weight of infected mice
significantly \((p=0.001)\). Although the XA monotherapy experiment did not significantly prevent weight loss, the combination therapy with ART and AQ showed significant reduction in weight loss in the 10.6 mg/kg and 12.1 mg/kg combination doses. This observation correlates with other studies where a combination of xylopic acid and cryptolepine prevented a loss in body weight in mice infected with \(P. \text{berghei} \text{ANKA}\) (12, 16).

All the characteristics of an ideal antimalaria agent should be able to prevent eventual death caused by parasites by suppressing the growth of parasites, thereby reducing the risk of death. An increase in parasite growth causes various symptoms of malaria which eventually leads to the death of the hosts (51). Hazard ratio is used in drug treatment to describe the relative risk of complication, when compared to event rates. In this study, the hazard ratio was measured to describe the outcome of the drug’s safety in the malaria treatment in relation to mice survival days. The XA and AQ monotherapy showed significant increase in the survival days for the middle doses while the high doses showed increased parasite clearance but reduced median survival days and increased hazard ratios. Notwithstanding, the high doses of ART treated group showed significant increased median survival days and reduced hazard ratio similar to AL. Surprisingly, in the combination therapy, the XA/ART treatment groups showed higher parasite clearance compared to XA/AQ, but their median survival day was only significant in the high doses with a mean hazard ratio 0.40, meanwhile, XA and AQ which showed significant increased survival days and reduced hazard ratio in only the middle doses during the monotherapy, had a significant increase in survival days for all the combination doses with a mean hazard ratio of 0.27 similar to AL. It is possible the early death of the animals in the XA/ART could have been due to toxicity of the combination since there was high parasite clearance (12, 52). AQ has been consistently reported to be relatively toxic (53, 54). Several studies indicate amodiaquine combination therapy could cause fetal death in animals, and indeed,
there have been reports of fetal resorption in early pregnancies (55). WHO, hence, recommends the avoidance of these drugs in the first trimester, but the problem can still exist if some women fail to recognize their conception at early stages. Notwithstanding, there was increased survival days for the xylopic acid-amodiaquine treated group in relation to the xylopic acid-артесуната treated groups, although, it had a lower parasite clearance. Thus, hypothetically, the combination of xylopic acid with AQ reduced the toxicity of AQ. Median survival for both AL and XA/AQ was statistically significant

CONCLUSION

The findings of this study is heartwarming in the light of the report of growing resistance to current artemisinin (56). The combination of xylopic acid with either amodiaquine or artesunate seemed to have increased efficacy since lower doses of each of the agents were required to produce a significant therapeutic effect, and also reduced toxicity in the xylopic acid and amodiaquine combination.

ABBREVIATIONS

ACTs: Artemisinin Based Combination therapies, ART: Artesunate, AQ: Amodiaquine, CPE: Cryptolepine, , DCTs: Drug combination therapies, ED\textsubscript{50}: Median effective dose, HSD: Honest significant difference, ICR: Institute for cancer research, LPS: Lipopolysaccharide, PBA: \textit{Plasmodium berghei} ANKA, pRBC: Parasitized red blood cells, SEM: Standard error of mean, SP: Sulfadoxine-pyrimethamine, XA: Xylopic acid, Z\textsubscript{add}: Theoretical ED\textsubscript{50}, Z\textsubscript{exp}: Experimental ED\textsubscript{50}
DECLARATION

Competing interests
The authors declare no competing interests in the work described here or the interpretation thereof.

Authors’ contributions
SAO performed all the technical work. SAO, RPB, and EOA performed statistical analysis, prepared most figures and guided interpretation and drafting of the results. SAO drafted the manuscript and oversaw the editing and revisions. EO and JNB assisted drafting and reviewing the manuscript. All authors reviewed and approved of the final manuscript.

Availability of data and materials
The data are available only upon request from the authors

Ethics approval and consent to participate
The activities described here did not include human subjects. All animals were gently handled in all experimental procedures per Animal Welfare Regulations (USDA 1985; US Code, 42 USC § 289d) and the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS 2002).

Acknowledgments
The authors appreciate the efforts of all technical staff of the Department of Biomedical Sciences.
REFERENCES

1. WHO. World malaria report 2015: World Health Organization; 2016.
2. W.H.O. World malaria report 2019. 2019.
3. Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS microbiology reviews. 2017;41(1):34-48.
4. Stewart B, Wild C. World Cancer Report 2014. Geneva: World Health Organization, International Agency for Research on Cancer. WHO Press; 2015.
5. Coelho CH, Doritchamou JYA, Zaidi I, Duffy PE. Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. Nature Publishing Group; 2017.
6. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, Binka F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. The Lancet infectious diseases. 2002;2(9):564-73.
7. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. The Journal of infectious diseases. 2003;188(8):1231-8.
8. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezhi G, Charlebois ED, et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. The Lancet. 2001;358(9279):368-74.
9. Zuber JA, Takala-Harrison S. Multidrug-resistant malaria and the impact of mass drug administration. Infection and drug resistance. 2018;11:299.
10. Kaur K, Jain M, Kaur T, Jain R. Antimalarials from nature. Bioorganic & medicinal chemistry. 2009;17(9):3229-56.
11. Boampong J, Ameyaw E, Aboagye B, Asare K, Kyei S, Donfack J, et al. The curative and prophylactic effects of xylopic acid on Plasmodium berghei infection in mice. Journal of parasitology research. 2013;2013.
12. Ameyaw EO, Asmah KB, Biney RP, Hennhe IT, Owusu-Agyei P, Prah J, et al. Isobolographic analysis of co-administration of two plant-derived antiplasmodial drug candidates, cryptolepine and xylopic acid, in Plasmodium berghei. Malaria journal. 2018;17(1):153.
13. Abiodun OO, Gbimadee N, Gbotosho GO. Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and artesunate in a mouse model of Plasmodium berghei. Journal of Chemotherapy. 2016;28(6):482-6.
14. Ameyaw EO, Woode E, Boakye-Gyasi E, Abotsi WK, Kyekyeku JO, Adosraku RK. Anti-allodynic and Anti-hyperalgesic effects of an ethanolic extract and xylopic acid from the fruits of Xylopia aethiopica in murine models of neuropathic pain. Pharmacognosy research. 2014;6(2):172.
15. Woode E, Ameyaw EO, Boakye-Gyasi E, Abotsi WK. Analgesic effects of an ethanol extract of the fruits of Xylopia aethiopica (Dunal) A. Rich (Annonaceae) and the major constituent, xylopic acid in murine models. Journal of pharmacy & bioallied sciences. 2012;4(4):291.
16. Woode E, Ameyaw EO, Boakye-Gyasi E, Abotsi WKM, Oppong Kyekyeku J, Adosraku R, et al. Effects of an ethanol extract and the diterpene, xylopic acid, of Xylopia aethiopica fruits in murine models of musculoskeletal pain. Pharmaceutical biology. 2016;54(12):2978-86.
17. Ishih A, Suzuki T, Hasegawa T, Kachi S, Wang H-h, Terada M. In vivo evaluation of combination effects of chloroquine with Cepharanthin® or minocycline hydrochloride against blood-induced chloroquine-resistant Plasmodium berghei NK 65 infections. Tropical Medicine and Health. 2004;32(1):15-9.
18. Nagamori Y. Transmission of Cytauxzoon felis by Amblyomma americanum: engorgement weight of nymphs and attachment time of adults for transmission to domestic cats 2016.
19. Dikasso D, Makonnen E, Debella A, Abebe D, Urga K, Makonnen W, et al. In vivo anti-malarial activity of hydroalcoholic extracts from Asparagus africanus Lam. in mice infected with Plasmodium berghei. Ethiopian Journal of Health Development. 2006;20(2):112-8.
20. Gupta P, Singh L, Singh K. The hybrid antimalarial approach. Annual Reports in Medicinal Chemistry. 53: Elsevier; 2019. p. 73-105.
21. Olasehinde GI, Ojurongbe O, Adeyeba AO, Fagade OE, Valecha N, Ayanda IO, et al. In vitro studies on the sensitivity pattern of Plasmodium falciparum to anti-malarial drugs and local herbal extracts. Malaria journal. 2014;13(1):63.
22. Burrows JN, Duparc S, Gutteridge WE, van Huijsduijnen RH, Kaszub ska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malaria journal. 2017;16(1):26.
23. Boakye-Gyasi E, Kasanga EA, Ameyaw EO, Abotsi WKM, Biney RP, Agyare C, et al. An isobolographic analysis of the anti-nociceptive effect of geraniin in combination with morphine or diclofenac. Journal of basic and clinical physiology and pharmacology. 2018;29(2):201-9.
24. Miranda HF, Prieto JC, Puig MM, Pinardi G. Isobolographic analysis of multimodal analgesia in an animal model of visceral acute pain. Pharmacology Biochemistry and Behavior. 2008;88(4):481-6.
25. Chou S, Marousek G, Auerochs S, Stamminger T, Milbradt J, Marschall M. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral research. 2011;92(2):364-8.
26. Mishra K, Dash AP, Dey N. Andrographolide: a novel antimalarial diterpene lactone compound from Andrographis paniculata and its interaction with curcumin and artesunate. Journal of tropical medicine. 2011;2011.
27. Okoye TC, Akah PA, Ezike AC, Uzor PF, Odoh UE, Igboeme SO, et al. Immunomodulatory effects of Stachy tarpheta cayennensis leaf extract and its synergistic effect with artesunate. BMC complementary and alternative medicine. 2014;14(1):1-8.
28. Santos JdO, Pereira GR, Brandão GC, Borgati TF, Arantes LM, Paula RCd, et al. Synthesis, in vitro antimalarial activity and in silico studies of hybrid kauranoid 1, 2, 3-triazoles derived from naturally occurring diterpenes. Journal of the Brazilian Chemical Society. 2016;27(3):551-65.
29. Tilley L, Charman SA, Vennerstrom JL. Semisynthetic artemisinin and synthetic peroxide antimalaria ls. RSC Drug Discovery Series. 2011(14):33-64.
30. Asawamahasakda W, Ittarat I, Pu Y-M, Ziffer H, Meshnick SR. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrobial agents and chemotherapy. 1994;38(8):1854-8.
31. Sharma V. Therapeutic drugs for targeting chloroquine resistance in malaria. Mini reviews in medicinal chemistry. 2005;5(4):337-51.
32. Osafo N, Obiri DD, Antwi AO, Yeboah OK. The acute anti-inflammatory action of xylopic acid isolated from Xylopia aethiopica. Journal of basic and clinical physiology and pharmacology. 2018;29(6):659-69.
33. Osafo N, Biney RP, Obiri DD. Aqueous ethanol fruit extract of Xylopia aethiopica and xylopic acid exhibit anti-inflammatory activity through inhibition of the arachidonic acid pathway. UK J Pharm Biosci. 2016;4:35-41.
34. Howland SW, Claser C, Poh CM, Gun SY, Rénia L, editors. Pathogenic CD8+ T cells in experimental cerebral malaria. Seminars in immunopathology; 2015: Springer.
35. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circulation research. 2004;95(9):858-66.
36. Hezi-Yamit A, Wong PW, Bien-Ly N, Komuves LG, Prasad KS, Phillips DR, et al. Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades. Proceedings of the National Academy of Sciences. 2005;102(34):12077-82.
37. Liu Y, Pelekanakis K, Woolkalis MJ. Thrombin and Tumor Necrosis Factor α Synergistically Stimulate Tissue Factor Expression in Human Endothelial Cells REGULATION THROUGH c-Fos AND c-Jun. Journal of Biological Chemistry. 2004;279(34):36142-7.
38. Shimizu T, Nishihira J, Watanabe H, Abe R, Honda A, Ishibashi T, et al. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. Journal of Biological Chemistry. 2004;279(14):13729-37.
39. Helmby H, Cavelier L, Pettersson U, Wahlgren M. Rosetting Plasmodium falciparum-infected erythrocytes express unique strain-specific antigens on their surface. Infection and Immunity. 1993;61(1):284-8.
40. Musasia FK. Antibody mediated clearance of ring-infected erythrocytes as a mechanism of protective immunity against Plasmodium falciparum malaria 2020.
41. Davis R. Cellular and Molecular Immunology: Scientific e-Resources; 2019.
42. Perkins DJ,Were T, Davenport GC, Kempaiah P, Hittner JB, Ong’echa JM. Severe malarial anemia: innate immunity and pathogenesis. International journal of biological sciences. 2011;7(9):1427.
43. Wykes MN, Horne-Debets JM, Leow C-Y, Karunarathne DS. Malaria drives T cells to exhaustion. Frontiers in microbiology. 2014;5:249.
44. Osafo N, Obiri DD. Anti-inflammatory and anti-anaphylactic activity of xylopic acid isolated from the dried fruit of Xylopia aethiopica in mice. Planta Med. 2016;81:S1-S381.
45. Mungthin M, Bray PG, Ridley RG, Ward SA. Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrobial agents and chemotherapy. 1998;42(11):2973-7.
46. Vale PF, McNally L, Doeschl-Wilson A, King KC, Popat R, Domingo-Sananes MR, et al. Beyond killing Can we find new ways to manage infection? Evolution, medicine, and public health. 2016;2016(1):148-57.
47. Li C, Sanni LA, Omer F, Riley E, Langhorne J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor β antibodies. Infection and immunity. 2003;71(9):4850-6.
48. Miller LH, Good MF, Milon G. Malaria pathogenesis. Science. 1994;264(5167):1878-83.
49. Segura M, Matte C, Thawani N, Su Z, Stevenson M. Modulation of malaria-induced immunopathology by concurrent gastrointestinal nematode infection in mice. International journal for parasitology. 2009;39(14):1525-32.
50. Thien HV, Kager PA, Sauerwein HP. Hypoglycemia in falciparum malaria: is fasting an unrecognized and insufficiently emphasized risk factor? Trends in parasitology. 2006;22(9):410-5.
51. Coban C, Lee MSJ, Ishii KJ. Tissue-specific immunopathology during malaria infection. Nature Reviews Immunology. 2018;18(4):266.
52. Alyousif MS, Saifi MA, Ahmed M, Alouyisif S. Histopathological changes induced by artesunate in liver of Wistar rat. Int J Pharmacol. 2017;13(1):104-8.
53. Lind D, Levi J, Vincent P. Amodiaquine-induced agranulocytosis: toxic effect of amodiaquine in bone marrow cultures in vitro. Br Med J. 1973;1(5851):458-60.
54. Tang Y, Wu Q, Beland FA, Chen S, Fang J-L. Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicology in Vitro. 2020;62:104669.
55. Angus B. Novel anti-malarial combinations and their toxicity. Expert review of clinical pharmacology. 2014;7(3):299-316.
56. Khera A, Mukherjee R. Artemisinin resistance: cause for worry? Journal of Marine Medical Society. 2019;21(1):4.